Kairos Pharma (KAPA) news

Pharmala Biotech Holdings Inc: Rua Bioscience and Pharmala Biotech partner to supply medicinal MDMA in New Zealand

PharmAla Biotech Holdings Inc. (CSE: MDMA) has partnered with Rua Bioscience to supply medicinal-grade MDMA to New Zealand, marking a significant step in the company’s international expansion. The collaboration aims to support clinical research and therapeutic applications of MDMA in the region,…

Circuitt Brewer: Kapa (AMEX) - Volatility trading pause

Circuitt Brewer, a provider of financial market data and analytics, has announced a temporary pause in volatility trading for Kapa (AMEX), effective immediately. The decision follows recent market fluctuations and increased volatility in the sector, prompting the firm to reassess risk management…

Kairos Pharma - Modifies phase 2 protocol to enroll patients earlier in disease progression

Kairos Pharma: 1-for-7 reverse stock split

Kairos Pharma Inc. (OTC: KPHR) has announced a 1-for-7 reverse stock split, effective as of the market open on August 22, 2026. The move is intended to comply with the minimum share price requirement set by the OTC Markets Group for continued listing [1]. The company stated that the reverse stock…

Kairos Pharma announces strategic collaboration with Bayer to enhance Xofingo activity in metastatic prostate cancer

Kairos Pharma Inc. (NASDAQ: KPHM) has announced a strategic collaboration with Bayer AG to investigate the potential of Xofingo, its proprietary phosphatidylserine-targeting immunotherapy, in the treatment of metastatic prostate cancer. The partnership aims to evaluate the drug’s activity in…